Avalo Therapeutics Files 2024 Proxy Statement
Ticker: AVTX · Form: DEF 14A · Filed: Jun 27, 2024 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | DEF 14A |
| Filed Date | Jun 27, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.001, $12,500 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
Related Tickers: AVLO
TL;DR
AVLO proxy statement filed. Annual meeting Aug 13. Vote your shares!
AI Summary
Avalo Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on June 27, 2024, for its annual meeting scheduled for August 13, 2024. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting. Avalo Therapeutics, Inc. is a pharmaceutical preparations company incorporated in Delaware.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including any proposals requiring a vote, and provides information on director nominations and executive compensation.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing for an annual meeting, not indicating any immediate financial distress or significant operational changes.
Key Numbers
- 20240813 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20240627 — Filing Date (The proxy statement was officially filed with the SEC on this date.)
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- 20240813 (date) — Annual Meeting Date
- 20240627 (date) — Filing Date
- Cerecor Inc. (company) — Former Company Name
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to solicit proxies from shareholders for the annual meeting of Avalo Therapeutics, Inc., scheduled for August 13, 2024.
When is the annual meeting of Avalo Therapeutics, Inc. scheduled to take place?
The annual meeting of Avalo Therapeutics, Inc. is scheduled to take place on August 13, 2024.
What was Avalo Therapeutics, Inc. formerly known as?
Avalo Therapeutics, Inc. was formerly known as Cerecor Inc.
On what date was this definitive proxy statement filed?
This definitive proxy statement was filed on June 27, 2024.
What is the Standard Industrial Classification (SIC) code for Avalo Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Avalo Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,845 words · 19 min read · ~16 pages · Grade level 12.7 · Accepted 2024-06-27 07:01:52
Key Financial Figures
- $0.001 — f the Company's common stock, par value $0.001 per share, outstanding and entitled to
- $12,500 — nd will pay them a fee of approximately $12,500 for such services. We may reimburse bro
Filing Documents
- def14a2024.htm (DEF 14A) — 3012KB
- avalo-logoxblk.jpg (GRAPHIC) — 47KB
- avalotherapeuticsinc_vxp001.jpg (GRAPHIC) — 152KB
- avalotherapeuticsinc_vxp002.jpg (GRAPHIC) — 114KB
- investordeck_pipelinechart.jpg (GRAPHIC) — 481KB
- pvpgraph_netlossa.jpg (GRAPHIC) — 54KB
- pvpgraph_tsra.jpg (GRAPHIC) — 48KB
- 0001628280-24-030232.txt ( ) — 4246KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 64 Executive Officers 64 Summary Compensation Table 64 Pay Versus Performance 66 Employment Agreements and Potential Payments Upon Certain Events 70 Outstanding Equity Awards at Fiscal Year-End 73 TRANSACTIONS WITH RELATED PERSONS 74 Related Person Transactions Policy and Procedures 74 Certain Related Person Transactions 74
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 76 HOUSEHOLDING OF PROXY MATERIALS 78 OTHER MATTERS 78 APPENDIX A - RISK FACTORS 79 APPENDIX B - AVALO THERAPEUTICS, INC. FINANCIAL STATEMENTS AND MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2023 115 APPENDIX C - AVALO THERAPEUTICS, INC. FINANCIAL STATEMENTS AND MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2024 153 APPENDIX D - ALMATABIO, INC. AUDITED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 AND FOR THE PERIOD FROM APRIL 28, 2023 (DATE OF INCEPTION) TO DECEMBER 31, 2023 181 APPENDIX E - UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION OF ALMATABIO, INC. AND AVALO THERAPEUTICS, INC. FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND FOR THE YEAR ENDED DECEMBER 31, 2023. 194 APPENDIX F - AVALO THERAPEUTICS, INC. FOURTH AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN 201 APPENDIX G - AVALO THERAPEUTICS, INC. AMENDED AND RESTATED 2016 EMPLOYEE STOCK PURCHASE PLAN 220 Table of Contents AVALO THERAPEUTICS, INC. 540 Gaither Road, Suite 400 Rockville, Maryland 20850 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS August 13, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the Internet Pursuant to rules adopted by the U.S. Securities and Exchange Commission (the "SEC"), we have elected to provide access to our proxy materials over the Internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the "Notice") because the board of directors (the "Board") of Avalo Therapeutics, Inc. (sometimes referred to as the "Company" or "Avalo") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders (the "Annual Meeting"), including at any adjournments or postponements of the Annual Me